$20.6 M

AKER Mkt cap, 22-Apr-2021
Akers Biosciences Net income (Q2, 2021)-18.1 M
Akers Biosciences EBIT (Q2, 2021)-18.3 M
Akers Biosciences Cash, 30-Jun-20212.1 M
Akers Biosciences EV18.5 M
Get notified regarding key financial metrics and revenue changes at Akers BiosciencesLearn more
Banner background

Akers Biosciences Revenue Breakdown

Embed Graph

Akers Biosciences revenue breakdown by business segment: 99.9% from Product and 0.1% from Other

Akers Biosciences Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

4.4m2.1m3.0m3.4m1.7m1.6m

Revenue growth, %

(52%)40%

Cost of goods sold

1.2m115.4k138.7k136.1k1.5m1.1m

Gross profit

3.3m2.0m2.8m3.2m127.3k478.7k

Gross profit Margin, %

73%95%95%96%8%30%

Sales and marketing expense

1.3m2.5m2.0m1.8m1.8m238.0k23.0k

R&D expense

916.3k1.4m1.2m1.2m1.1m276.8k8.0m

General and administrative expense

3.8m4.0m3.0m4.1m5.7m3.7m4.3m

Operating expense total

6.5m10.8m5.2m7.6m10.2m4.4m12.3m

Depreciation and amortization

236.7k171.1k171.1k171.1k40.0k

EBIT

(3.2m)(9.7m)(3.3m)(6.6m)(10.1m)(3.9m)(12.3m)

EBIT margin, %

(72%)(458%)(112%)(197%)(604%)(250%)

Interest expense

788.6k

Interest income

69.6k102.5k21.7k

Pre tax profit

(3.1m)(9.3m)(3.3m)(7.4m)(10.8m)(3.9m)(12.2m)

Income tax expense

1.3m(269.3k)895.0k(6.0m)(2.9m)(738.0k)(2.0m)

Net Income

(3.1m)(9.3m)(3.3m)(7.4m)(10.8m)(3.9m)(17.6m)

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Revenue

1.2m1.4m453.3k510.0k966.9k169.5k738.0k956.5k613.2k667.3k1.2m675.8k302.5k526.6k557.1k612.1k464.5k420.8k363.5k(1.9k)

Cost of goods sold

604.3k141.4k162.1k226.3k341.0k178.0k21.7k47.0k19.4k16.2k31.4k16.1k297.5k302.8k476.5k245.9k219.9k285.5k172.9k377.2k

Gross profit

569.6k1.2m291.2k283.7k625.9k(8.5k)716.3k909.5k593.8k651.1k1.2m659.7k5.0k223.8k80.6k366.2k244.6k135.3k190.6k(379.1k)

Gross profit Margin, %

49%90%64%56%65%(5%)97%95%97%98%97%98%2%42%14%60%53%32%52%20077%

Sales and marketing expense

211.1k396.6k358.7k575.3k553.5k725.8k725.3k513.4k408.2k556.7k354.9k342.8k468.5k442.4k382.0k149.8k14.1k38.3k14.5k7.2k6.3k

R&D expense

253.5k249.0k183.9k305.6k378.2k319.6k363.3k322.0k247.6k348.4k290.8k290.4k391.4k253.4k160.9k88.4k60.9k57.5k2.5m1.9m1.7m

General and administrative expense

458.7k1.0m826.8k698.4k882.5k760.3k923.6k816.2k558.3k790.5k829.9k819.6k915.5k1.6m1.7m983.0k981.3k895.0k1.2m736.7k1.2m1.5m1.7m

Operating expense total

1.2m1.7m1.4m1.6m2.7m2.3m2.1m1.7m75.2k1.8m1.6m1.5m1.9m2.3m3.2m1.3m1.1m1.0m3.7m3.3m3.0m1.5m1.7m

Depreciation and amortization

64.6k64.6k64.6k64.6k42.8k42.8k42.8k42.8k42.8k42.8k42.8k10.0k10.0k8.9k8.7k

EBIT

(613.4k)(515.5k)(1.1m)(1.4m)(2.1m)(2.3m)(1.5m)(1.0m)301.3k(1.4m)(669.3k)(1.2m)(1.9m)(2.1m)(3.1m)(940.0k)(821.7k)(865.5k)(3.5m)(3.7m)(3.0m)(1.5m)(18.3m)

EBIT margin, %

(52%)(38%)(252%)(267%)(219%)(1384%)(206%)(106%)49%(204%)(56%)(174%)(626%)(401%)(561%)(154%)(177%)(206%)(975%)193711%

Interest expense

30.8k5.9k45.7k

Interest income

37.1k20.5k10.3k8.4k5.3k2.5k3.6k3.1k5.6k

Pre tax profit

(595.6k)(495.0k)(1.1m)(1.3m)(2.1m)(2.3m)(1.5m)(1.0m)310.2k(1.3m)(666.6k)(1.2m)(1.9m)(2.1m)(3.1m)(917.0k)(794.9k)(837.0k)(3.5m)(3.6m)(2.9m)(1.4m)(18.1m)

Income tax expense

Net Income

(595.6k)(510.8k)(1.1m)(1.3m)(2.1m)(2.3m)(1.5m)(1.0m)310.2k(1.3m)(666.6k)(1.2m)(1.9m)(2.1m)(3.1m)(917.0k)(794.9k)(837.0k)(3.5m)(3.6m)(7.1m)(1.5m)(18.1m)

Akers Biosciences Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

455.8k402.1k72.7k438.4k181.8k517.4k18.6m

Accounts Receivable

2.0m609.2k601.3k964.7k176.3k42.9k1.2m

Prepaid Expenses

145.5k444.4k387.2k294.3k

Inventories

905.1k1.1m2.0m947.6k585.3k199.0k

Current Assets

13.1m6.5m3.2m7.8m6.7m10.3m36.8m

PP&E

201.5k251.1k259.4k235.1k83.5k33.6k

Total Assets

16.7m8.3m5.1m9.3m7.8m10.9m36.8m

Accounts Payable

1.5m1.7m97.8m1.7m2.0m1.5m2.2m

Current Liabilities

1.8m1.7m1.7m1.8m1.5m2.3m

Total Liabilities

1.8m1.7m1.7m1.8m2.0m1.5m2.3m

Common Stock

99.7m100.8m110.6m121.6m128.9m171.6m

Preferred Stock

1.8m

Retained Earnings

(84.9m)(94.2m)(97.5m)(104.8m)(115.7m)(119.6m)(137.2m)

Total Equity

14.8m6.6m3.4m7.6m5.8m9.4m34.6m

Financial Leverage

1.1 x1.3 x1.5 x1.2 x1.3 x1.2 x1.1 x

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Cash

305.8k402.3k642.5k336.2k261.2k393.4k180.4k379.5k195.9k2.1m197.2k135.1k647.3k276.0k1.3m275.5k248.4k363.3k812.4k11.4m16.2m569.4k2.1m

Accounts Receivable

138.6k1.0m1.1m1.1m1.9m1.1m781.7k542.5k738.2k517.1k927.5k1.1m416.9k412.6k283.2k324.5k266.9k230.9k321.6k2.3k3.0m

Prepaid Expenses

175.5k138.3k142.0k94.3k98.3k147.5k99.5k235.0k693.6k513.3k283.4k169.6k463.9k339.5k172.1k446.5k214.1k744.6k

Inventories

665.1k752.6k784.9k969.9k822.0k955.2k1.2m1.2m1.9m2.2m2.2m2.1m973.9k1.0m808.0k601.3k544.2k412.1k193.4k

Current Assets

15.2m15.2m14.3m11.8m9.9m8.3m4.8m3.9m3.8m5.3m4.9m4.0m11.2m10.6m7.9m6.0m5.2m4.3m8.3m18.5m23.6m34.3m22.4m

PP&E

245.1k224.6k224.7k230.3k214.3k214.2k321.2k304.3k245.6k258.2k260.8k242.0k259.3k245.5k258.6k78.0k68.5k58.9k26.7k4.8k3.7k

Goodwill

10.5m

Total Assets

17.8m17.8m16.8m15.4m13.3m11.1m6.7m5.7m5.8m7.1m6.6m5.5m12.8m12.6m10.0m7.0m5.9m5.0m9.1m18.7m23.7m35.8m34.4m

Accounts Payable

148.2k290.1k251.7k928.9k1.2m1.3m1.5m1.6m1.2m1.3m1.4m1.5m1.4m1.8m2.3m2.1m1.6m1.4m2.0m2.6m1.1m2.3m3.3m

Short-term debt

146.1k80.0k40.5k49.5k

Current Liabilities

943.3k971.5k999.4k1.2m1.2m1.3m1.5m1.6m1.3m1.4m1.4m1.6m1.4m1.9m2.3m1.4m2.2m2.7m2.6m2.4m3.3m

Long-term debt

124.4k80.0k40.5k25.9k

Non-Current Liabilities

222.2k138.9k55.6k25.9k

Total Debt

270.5k160.0k81.0k75.4k

Total Liabilities

1.2m1.1m1.1m1.2m1.2m1.3m1.5m1.6m1.3m1.4m1.4m1.6m1.4m1.9m2.3m2.1m1.6m1.4m2.3m2.7m2.6m2.4m3.4m

Common Stock

98.9m99.5m99.7m100.4m100.4m100.4m100.8m100.8m100.9m104.6m104.6m104.6m118.1m119.6m119.6m121.6m121.7m121.8m129.7m142.3m154.9m171.9m

Preferred Stock

Retained Earnings

(82.3m)(82.8m)(84.0m)(86.2m)(88.3m)(90.6m)(95.7m)(96.7m)(96.4m)(98.8m)(99.5m)(100.7m)(106.7m)(108.8m)(111.9m)(116.6m)(117.4m)(118.2m)(123.1m)(126.7m)(133.9m)(138.6m)(69.9m)

Total Equity

16.6m16.7m15.7m14.2m12.1m9.8m5.1m4.1m4.5m5.7m5.1m3.9m11.4m10.8m7.7m5.0m4.3m3.6m6.8m16.0m21.2m33.4m31.1m

Debt to Equity Ratio

0 x

Debt to Assets Ratio

0 x

Financial Leverage

1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.3 x1.4 x1.3 x1.2 x1.3 x1.4 x1.1 x1.2 x1.3 x1.4 x1.4 x1.4 x1.3 x1.2 x1.1 x1.1 x1.1 x

Akers Biosciences Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(3.1m)(9.3m)(3.3m)(7.4m)(10.8m)(3.9m)(12.2m)

Depreciation and Amortization

349.4k300.0k286.2k249.9k234.5k74.1k29.5k

Accounts Receivable

(1.9m)513.6k(138.3k)(813.4k)631.5k128.1k42.9k

Inventories

123.0k(226.5k)(187.2k)(119.6k)(83.3k)14.3k1.3k

Accounts Payable

538.0k827.6k(205.4k)281.9k188.5k(443.7k)733.5k

Cash From Operating Activities

(3.9m)(5.1m)(4.2m)(5.1m)(8.5m)(3.1m)(11.9m)

Purchases of PP&E

(25.0k)(113.0k)(123.3k)(54.5k)(68.2k)

Cash From Investing Activities

(9.3m)5.1m3.8m(5.0m)(344.5k)(3.9m)(8.8m)

Short-term Borrowings

(307.5k)

Dividends Paid

(15.8k)

Cash From Financing Activities

13.5m10.5m9.1m7.0m38.7m

Net Change in Cash

352.2k(53.8k)(329.4k)365.7k243.3k(49.2k)18.0m

Income Taxes Paid

1.3m2.1k

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Net Income

(595.6k)(1.1m)(2.2m)(1.3m)(3.4m)(5.7m)(1.5m)(2.5m)(2.2m)(1.3m)(2.0m)(3.2m)(1.9m)(3.9m)(7.0m)(917.0k)(1.7m)(2.5m)(3.5m)(7.2m)(9.0m)(1.4m)(21.2m)

Depreciation and Amortization

86.8k173.6k261.5k80.3k160.9k241.5k56.5k113.9k221.9k60.7k121.4k182.9k56.5k112.9k173.0k15.4k35.0k54.5k15.8k27.7k28.8k

Accounts Receivable

(20.2k)(926.8k)(958.1k)20.0k(747.6k)45.1k(172.5k)(79.9k)(275.5k)43.4k(372.5k)(570.1k)547.8k455.0k584.4k(152.4k)(94.8k)(59.9k)(278.7k)63.5k67.1k

Inventories

360.0k272.5k240.2k(64.8k)83.1k(50.0k)(80.5k)(85.6k)(60.9k)(100.9k)151.7k(49.3k)(50.8k)(99.2k)(79.2k)(16.0k)41.0k46.8k1.7k1.3k1.3k

Accounts Payable

(390.4k)(362.2k)(334.4k)87.7k323.8k415.2k(125.6k)(103.0k)(419.0k)(200.1k)50.2k85.7k(384.7k)90.0k509.0k107.2k(355.8k)(600.5k)504.1k1.1m961.1k(1.4m)(2.0m)

Cash From Operating Activities

(832.4k)(1.8m)(2.8m)(1.2m)(3.0m)(4.0m)(1.7m)(2.4m)(3.5m)(1.6m)(2.6m)(3.7m)(1.8m)(3.8m)(5.9m)(748.7k)(1.6m)(2.6m)(2.0m)(3.9m)(8.8m)(2.5m)(8.3m)

Purchases of PP&E

(1.7k)(25.0k)(44.5k)(44.5k)(60.3k)(83.8k)(81.5k)(88.0k)(16.8k)(37.2k)(37.2k)(37.8k)(37.7k)(68.2k)

Cash From Investing Activities

(12.5m)(11.4m)(10.2m)1.1m2.8m3.9m1.5m2.4m3.3m(123.8k)(996.8k)2.8k(3.7m)(3.0m)82.5k822.5k1.3m2.4m2.3m2.2m2.2m(15.6m)11.4m

Short-term Borrowings

(307.5k)(307.5k)(307.5k)

Long-term Borrowings

(3.1m)

Dividends Paid

(15.8k)(15.8k)

Cash From Financing Activities

13.5m13.5m13.5m3.7m3.7m3.7m5.7m7.2m7.2m77.012.6m22.3m(1.1m)

Net Change in Cash

202.2k298.6k538.9k(119.6k)(194.6k)(62.5k)(221.7k)(22.5k)(206.2k)2.0m124.5k62.4k208.8k337.5k1.4m73.8k(318.2k)(203.4k)295.0k10.9m15.7m(18.0m)2.0m

Interest Paid

271.8k

Akers Biosciences Ratios

USDQ1, 2014

Financial Leverage

1.1 x